Redeye comments on Nanologica following the annonucement of a SEK8.
Redeye comments on Sivers Semiconductors following the announcement that the company will receive an...
Redeye comments on SciBase’s announcement of its preliminary results for the capital raise this morn...
Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered into a non-bi...
Redeye endorses today’s news that Elicera has received an orphan drug designation in the US for ELC-...
Redeye expects a stable Q4 report from Sdiptech but with tough comparables weighing negatively.
Redeye initiates coverage of OEM International, a niche acquirer of technology trading SMEs that has...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 10 januari 2025 att Bolaget har erhållit ty...
Redeye comments on yesterday’s news from FMG, where it expects to be negatively impacted by reduced ...
Redeye comments on SynAct’s successful rights issue.
Nexttobe, existing investor Ulf Landegren, certain board members, senior executives and guarantee co...
Redeye provides a short comment on the trading update from Cheffelo released earlier this morning.
Redeye retains its Q4 and 2025 forecasts for Transtema.
Q4 report due 18 February We forecast net sales of SEK 189m, EBITA of SEK 27m Trading near low end o...
Redeye comments on the new data from the triple combination study of BI-1206 and the phase I monothe...
